Selux Diagnostics

Provides rapid antibiotic susceptibility testing

Boston, Massachusetts, United States

About Selux Diagnostics

Selux Diagnostics focuses on antibiotic susceptibility testing (AST) to address the growing issue of antimicrobial resistance (AMR). The company provides healthcare providers, particularly hospitals, with rapid and comprehensive testing services that evaluate the effectiveness of various antibiotics against bacteria. This technology allows for simultaneous testing against all relevant antibiotics, which is a significant advancement in a field that has seen little innovation in recent years. By delivering faster diagnostic results, Selux helps ensure that patients receive the correct antibiotics, reducing the risk of ineffective prescriptions. The goal of Selux Diagnostics is to preserve the effectiveness of antibiotics for future generations and combat the global health crisis posed by AMR.

Boston, MassachusettsHeadquarters
2014Year Founded
$175MTotal Funding
LATE_VCCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Health Insurance
401(k) Company Match
Unlimited Paid Time Off
Parental Leave

Risks

Increased competition in the rapid AST market threatens Selux's market share.
Reliance on continuous funding poses financial risks if future funding is challenging.
Potential FDA approval delays could hinder product expansion and competitiveness.

Differentiation

Selux offers the only single-platform technology for rapid AST from blood cultures.
Their Next Generation Phenotyping platform provides personalized antimicrobial therapies quickly.
Selux's AST technology tests against all commercially relevant antibiotics simultaneously.

Upsides

Recent $48 million funding round supports aggressive expansion and product development.
FDA clearance for Gram-Negative Panel enhances Selux's comprehensive AST platform.
Growing demand for rapid diagnostics boosts Selux's market potential.